What are The Most Effective Pharmacological and Non-Pharmacological Interventions for Managing Progression of Cerebral Atrophy in Patients with Neurodegenerative Disorders? : A Systematic Review
Keywords:
Cerebral Atrophy, Neurodegenerative Disorders, Pharmacological Interventions, Non-Pharmacological Interventions, Alzheimer's Disease, Multiple Sclerosis, Brain VolumeAbstract
Introduction: Cerebral atrophy, a hallmark of neurodegenerative disorders like Alzheimer's (AD) and multiple sclerosis (MS), leads to cognitive and functional decline. Identifying effective pharmacological and non-pharmacological interventions to slow this progression is crucial for improving patient outcomes. Methods: This systematic review followed PRISMA 2020 guidelines, including RCTs, systematic reviews, meta-analyses, or longitudinal observational studies of adults with neurodegenerative disorders. Studies required validated neuroimaging (MRI/CT) for atrophy assessment, minimum 6-month follow-up, and quantitative brain volume measures. A PICO-based keyword strategy was used for database searches. Results: Thirty-one studies were included, predominantly focusing on MS and AD. Pharmacological interventions, especially in MS, consistently reduced brain atrophy rates. Cholinesterase inhibitors and memantine showed small but significant effects in AD. Non-pharmacological interventions like exercise and cognitive rehabilitation preserved brain structure and improved function, particularly in early-stage disease or cognitively impaired individuals. Combined interventions showed additional benefits in AD. Discussion: Pharmacological agents like siponimod and ibudilast demonstrated robust atrophy reduction in MS. In AD, cholinesterase inhibitors and choline precursors reduced gray matter atrophy. Non-pharmacological approaches, such as exercise with music, preserved medial temporal lobe integrity and daily living activities. While direct comparisons are sparse, pharmacological interventions appear more potent in MS, while combined approaches excel in AD. Early intervention and patient neural reserve significantly influence efficacy. Conclusion: Effective cerebral atrophy management demands disease-specific, early, and tailored interventions. Pharmacological interventions show strong structural benefits in MS and AD, while non-pharmacological and multimodal approaches offer complementary advantages, especially in early-stage disease. Future research should prioritize head-to-head comparisons to optimize treatment protocols and improve long-term outcomes.
References
A. Daniele, and F. Panza. “Can a Cognitive Rehabilitation Program in Early Stages of Parkinson's Disease Improve Cognition, Apathy and Brain Functional Connectivity for up to 18 Months?” European Journal of Neurology, 2018.
A. Eshaghi, R. Kievit, R. Kievit, F. Prados, F. Prados, Carole H. Sudre, Carole H. Sudre, et al. “Applying Causal Models to Explore the Mechanism of Action of Simvastatin in Progressive Multiple Sclerosis.” Proceedings of the National Academy of Sciences of the United States of America, 2019.
A. S. Gravesteijn, H. Beckerman, B. A. D. Jong, H. Hulst, and V. D. Groot. “Neuroprotective Effects of Exercise in People with Progressive Multiple Sclerosis (Exercise PRO-MS): Study Protocol of a Phase II Trial.” BMC Neurology, 2020.
Danielle M. Bartlett, A. Govus, T. Rankin, A. Lampit, K. Feindel, G. Poudel, W. Teo, et al. “The Ef- fects of Multidisciplinary Rehabilitation on Neuroimaging, Biological, Cognitive and Motor Outcomes in Individuals with Premanifest Huntington's Disease.” Journal of Neurological Sciences, 2020.
. Ciampi, R. Uribe-San-Martin, C. Cárcamo, J. Cruz, A. Reyes, D. Reyes, C. Pinto, M. Vasquez, R. Burgos, and J. Hancke. “Efficacy of Andrographolide in Not Active Progressive Multiple Sclerosis: A Prospective Exploratory Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Trial.” BMC Neurology, 2020.
E. Traini, A. Carotenuto, A. Fasanaro, and F. Amenta. “Volume Analysis of Brain Cognitive Areas in Alzheimer’s Disease: Interim 3-Year Results from the ASCOMALVA Trial.” Journal of Alzheimer's Disease, 2020.
E. Traini, A. Carotenuto, A. Fasanaro, R. Rea, and F. Amenta. “Brain Volume Changes in Alzheimer’s Dis- ease Patients Treated with a Cholinesterase Inhibitor Plus the Cholinergic Precursor Choline Alphoscer- ate,” 2015.
Elizabeth Fisher, Kunio Nakamura, Jar‐chi Lee, X. You, Bjørn Sperling, and R. Rudick. “Effect of In- tramuscular Interferon Beta-1a on Gray Matter Atrophy in Relapsing−remitting Multiple Sclerosis: A Retrospective Analysis.” Multiple Sclerosis, 2016.
F. Panza, M. Lozupone, Vittorio Dibello, A. Greco, A. Daniele, D. Seripa, G. Logroscino, and B. Imbimbo. “Are Antibodies Directed Against Amyloid- (A ) Oligomers the Last Call for the A Hypothesis of Alzheimer's Disease?” Immunotherapy, 2019.
G. Tsivgoulis, A. Katsanos, N. Grigoriadis, Georgios M. Hadjigeorgiou, I. Heliopoulos, Panagiotis Pap- athanasopoulos, E. Dardiotis, C. Kilidireas, and K. Voumvourakis. “The Effect of Disease-Modifying Therapies on Brain Atrophy in Patients with Clinically Isolated Syndrome: A Systematic Review and Meta-Analysis.” Therapeutic Advances in Neurological Disorders, 2015.
H. R. C. Shanks, Kewei Chen, Eric M Reiman, K. Blennow, Jeffrey L. Cummings, S. Massa, Frank M. Longo, Anne Börjesson-Hanson, Manfred Windisch, and Taylor W. Schmitz. “P75 Neurotrophin Receptor Modulation in Mild to Moderate Alzheimer Disease: A Randomized, Placebo-Controlled Phase 2a Trial.” Nature Network Boston, 2024.
I. Harding, Joanne Ryan, Stephane Heritier, Simone Spark, Zachary Flanagan, Richard McIntyre, Craig S. Anderson, et al. “STAREE-Mind Imaging Study: A Randomised Placebo-Controlled Trial of Atorvastatin for Prevention of Cerebrovascular Decline and Neurodegeneration in Older Individuals.” BMJ Neurology Open, 2023.
J. Chataway, Jennifer M. Nicholas, Julie Wych, N. Schuerer, A. Alsanousi, D. Chan, D. MacManus, et al. “Smaller Baseline Brain Volume and Higher Atrophy Rate over Two Years Is Associated with Poorer Clinical Outcomes: Post Hoc Analysis of the MS-STAT Trial in Secondary Progressive MS (P7.259).” Neurology, 2015.
K. Tabei, M. Satoh, Jun-ichi Ogawa, T. Tokita, N. Nakaguchi, K. Nakao, H. Kida, and H. Tomimoto. “Cognitive Function and Brain Atrophy Predict Non-Pharmacological Efficacy in Dementia: The Mihama- Kiho Scan Project2.” Frontiers in Aging Neuroscience, 2018.
L. Schneider, Y. Geffen, J. Rabinowitz, Ronald G. Thomas, R. Schmidt, S. Ropele, and M. Weinstock. “Low-Dose Ladostigil for Mild Cognitive Impairment.” Neurology, 2019.
Lisa Perus, Germain U. Busto, J. F. Mangin, E. Le Bars, and A. Gabelle. “Effects of Preventive Interventions on Neuroimaging Biomarkers in Subjects at-Risk to Develop Alzheimer's Disease: A Systematic Review.” Frontiers in Aging Neuroscience, 2022.
M. Langeskov-Christensen, Lars Grøndahl Hvid, M. Nygaard, S. Ringgaard, H. Jensen, H. H. Nielsen, T. Petersen, E. Stenager, S. Eskildsen, and U. Dalgas. “Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis.” Neurology, 2020.
M. Satoh, Jun-ichi Ogawa, T. Tokita, N. Nakaguchi, K. Nakao, H. Kida, and H. Tomimoto. “Physical Exercise with Music Maintains Activities of Daily Living in Patients with Dementia: Mihama-Kiho Project Part 2.” Journal of Neurological Sciences, 2017.
María Díez-Cirarda, N. Ibarretxe‐Bilbao, J. Peña, and N. Ojeda. “Efficacy of Cognitive Rehabilitation in Parkinson's Disease.” Neural Regeneration Research, 2018.
Nicole Last, E. Tufts, and Leslie E. Auger. “The Effects of Meditation on Grey Matter Atrophy and Neurodegeneration: A Systematic Review.” Journal of Parkinson's Disease, 2016.
P. Connick, F. De Angelis, R. Parker, D. Plantone, A. Doshi, N. John, J. Stutters, et al. “Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): A Multiarm Phase IIb Randomised, Double-Blind, Placebo-Controlled Clinical Trial Comparing the Efficacy of Three Neuro- protective Drugs in Secondary Progressive Multiple Sclerosis.” BMJ Open, 2018.
R. Fox, Akshata Ashokkumar, Janel Barnes, Marianne K Chase, C. Coffey, R. Conwit, M. Cudkowicz, et al. “A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis (CT.004).” Neurology, 2018.
R. Fox, D. Arnold, G. Giovannoni, B. Cree, P. Vermersch, A. Bar-Or, R. Gold, et al. “Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130).” Neurology, 2020.
R. Sivera, N. Capet, V. Manera, R. Fabre, Marco Lorenzi, H. Delingette, X. Pennec, N. Ayache, and P. Robert. “Voxel Based Assessments of Treatment Effects on Longitudinal Brain Changes in the MAPT Cohort,” 2019.
S. Schobel, G. Palermo, P. Auinger, J. Long, Shiyang Ma, O. Khwaja, D. Trundell, et al. “Motor, Cognitive, and Functional Declines Contribute to a Single Progressive Factor in Early HD.” Neurology, 2017.
Sonia Di Tella, M. Cabinio, Sara Isernia, V. Blasi, Federica Rossetto, F. L. Saibene, M. Alberoni, et al. “Neuroimaging Biomarkers Predicting the Efficacy of Multimodal Rehabilitative Intervention in the Alzheimer’s Dementia Continuum Pathology.” Frontiers in Aging Neuroscience, 2021.
T. Kishi, S. Matsunaga, K. Oya, T. Ikuta, and N. Iwata. “Protection Against Brain Atrophy by Anti- Dementia Medication in Mild Cognitive Impairment and Alzheimer’s Disease: Meta-Analysis of Lon- gitudinal Randomized Placebo-Controlled Trials.” International Journal of Neuropsychopharmacology, 2015.
Xiao Da, E. Hempel, Yangming Ou, Olivia Elizabeth Rowe, Zach Malchano, Mihály Hajós, Ralph Kern, J. Megerian, and Aylin Cimenser. “Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease.” Journal of Alzheimer's Disease, 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Franky Abryanto, Anistia Wigata, Susi Susanti Gurning (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
